$21.03
4.11% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Viridian Therapeutics Inc Stock price

$21.03
-2.02 8.76% 1M
+8.92 73.66% 6M
-0.75 3.44% YTD
+5.12 32.18% 1Y
+1.65 8.51% 3Y
+10.83 106.18% 5Y
-676.94 96.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.83 4.11%
ISIN
US92790C1045
Symbol
VRDN
Sector
Industry

Key metrics

Market capitalization $1.67b
Enterprise Value $1.12b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3,749.20
P/S ratio (TTM) P/S ratio 5,552.80
P/B ratio (TTM) P/B ratio 3.21
Revenue growth (TTM) Revenue growth -12.97%
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-283.04m
Free Cash Flow (TTM) Free Cash Flow $-197.43m
Cash position $753.24m
EPS (TTM) EPS $-4.31
P/E forward negative
P/S forward 5,297.98
EV/Sales forward 3,577.15
Short interest 14.98%
Show more

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.30 0.30
14% 14%
100%
- Direct Costs 1.57 1.57
-
523%
-1.27 -1.27
-
-423%
- Selling and Administrative Expenses 76 76
9% 9%
25,343%
- Research and Development Expense 204 204
28% 28%
68,063%
-281 -281
22% 22%
-93,827%
- Depreciation and Amortization 1.57 1.57
34% 34%
523%
EBIT (Operating Income) EBIT -283 -283
22% 22%
-94,348%
Net Profit -257 -257
19% 19%
-85,693%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Neutral
Business Wire
21 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of no...
Positive
Seeking Alpha
about one month ago
Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has ...
Positive
Seeking Alpha
2 months ago
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the para...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Stephen Mahoney
Employees 96
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today